潰瘍性結腸炎市場－全球產業規模、佔有率、趨勢、機會和預測，依藥物類型、疾病類型、地區和競爭格局分類。 2021-2031年預測

全球潰瘍性結腸炎市場規模將從2025年的80.6億美元成長到2031年的113.6億美元，複合年成長率為5.89%。潰瘍性結腸炎是一種慢性發炎性腸道疾病，其特徵是結腸和直腸持續發炎和黏膜潰瘍，因此對包括氨基水楊酸鹽、皮質類固醇和先進生物製劑在內的藥物療法有著持續的需求。

主要市場促進因素

新型生物製劑和小分子療法的加速核准是市場擴張的主要催化劑，直接滿足了對傳統療法無效患者的臨床需求。監管機構擴大批准具有不同作用機制的藥物，例如白細胞介素-23抑制劑和Janus激酶抑制劑，這豐富了胃腸病學家可用的治療手段。

主要市場挑戰

新型生物製劑和小分子療法的高昂價格嚴重限制了全球潰瘍性結腸炎市場的成長。儘管這些先進療法能夠帶來必要的臨床緩解，但其高昂的費用迫使公共和私人支付方實施嚴格的成本控制措施，例如分級納入藥品目錄和嚴格的預先核准要求。

主要市場趨勢

經濟實惠的生物相似藥的湧現，正在從根本上重塑全球潰瘍性結腸炎市場，打破現有重磅藥物的專利壟斷地位。隨著烏司奴單抗和阿達木單抗等旗艦療法的專利保護到期，高品質生物相似藥的積極進入市場，加劇了價格競爭，並擴大了此前因價格高昂而難以獲得生物製劑治療的患者群體。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球潰瘍性結腸炎市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依藥物類型（抗發炎藥、抗TNF生物製劑、免疫抑制劑、鈣調磷酸酶抑制劑及其他）
  • 依疾病類型（潰瘍性直腸炎、直腸乙狀結腸炎、左側結腸炎、全結腸炎或普遍性結腸炎、暴發性結腸炎）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美潰瘍性結腸炎市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲潰瘍性結腸炎市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區潰瘍性結腸炎市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲潰瘍性結腸炎市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲潰瘍性結腸炎市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球潰瘍性結腸炎市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Johnson and Johnson
• Allergan, Inc.
• Merck & Co., Inc.
• Novartis AG
• Bausch Health Companies Inc.
• AstraZeneca Plc
• Eli Lilly & Company
• Pfizer Inc.
• Sanofi SA
• GlaxoSmithKline Plc.

第16章：策略建議

第17章調查會社について,免責事項

The Global Ulcerative Colitis Market will grow from USD 8.06 Billion in 2025 to USD 11.36 Billion by 2031 at a 5.89% CAGR. Ulcerative colitis is a chronic inflammatory bowel disease characterized by continuous inflammation and mucosal ulceration in the colon and rectum, creating a sustained demand for pharmacotherapies including aminosalicylates, corticosteroids, and advanced biologics.

Key Market Drivers

The accelerated approval of novel biologics and small molecule therapies serves as a primary catalyst for market expansion, directly addressing the clinical needs of patients refractory to conventional treatments. Regulatory agencies are increasingly authorizing agents with distinct mechanisms of action, such as interleukin-23 inhibitors and Janus kinase inhibitors, which diversifies the therapeutic arsenal available to gastroenterologists. This regulatory momentum ensures a steady influx of advanced treatment options that offer improved remission rates and safety profiles, encouraging healthcare providers to switch patients from older protocols to newer, more effective regimens.

Key Market Challenges

The prohibitive pricing of novel biologic and small molecule therapies constitutes a severe restraint on the growth of the global ulcerative colitis market. Although these advanced treatments provide necessary clinical remission, their substantial costs compel public and private payers to implement stringent cost-containment measures, such as tiered formulary placement and rigorous prior authorization requirements. These financial barriers frequently force physicians to reserve high-efficacy drugs for only the most severe cases, effectively capping the sales volume of premium products and slowing revenue generation across the sector.

Key Market Trends

The proliferation of cost-effective biosimilars for major biologics is fundamentally reshaping the global ulcerative colitis market by dismantling the exclusivity of incumbent blockbusters. As patent protections for flagship therapies like ustekinumab and adalimumab expire, the aggressive entry of high-quality biosimilars is driving price competition and expanding patient access to biologic treatments previously restricted by prohibitive costs.

Key Market Players

• Johnson and Johnson
• Allergan, Inc.
• Merck & Co., Inc.
• Novartis AG
• Bausch Health Companies Inc.
• AstraZeneca Plc
• Eli Lilly & Company
• Pfizer Inc.
• Sanofi SA
• GlaxoSmithKline Plc.

Report Scope:

In this report, the Global Ulcerative Colitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ulcerative Colitis Market, By Drug Type:

• Anti-Inflammatory Drugs
• Anti-TNF biologics
• Immuno-suppressants
• Calcineurin Inhibitors
• and Other

Ulcerative Colitis Market, By Disease Type:

• Ulcerative Proctitis
• Proctosigmoiditis
• Left-sided Colitis
• Pancolitis or Universal Colitis
• and Fulminant Colitis

Ulcerative Colitis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ulcerative Colitis Market.

Available Customizations:

Global Ulcerative Colitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ulcerative Colitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Anti-Inflammatory Drugs, Anti-TNF biologics, Immuno-suppressants, Calcineurin Inhibitors, and Other)
  • 5.2.2. By Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Ulcerative Colitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Ulcerative Colitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Disease Type
  • 6.3.2. Canada Ulcerative Colitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Disease Type
  • 6.3.3. Mexico Ulcerative Colitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Disease Type

7. Europe Ulcerative Colitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Ulcerative Colitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Disease Type
  • 7.3.2. France Ulcerative Colitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Disease Type
  • 7.3.3. United Kingdom Ulcerative Colitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Disease Type
  • 7.3.4. Italy Ulcerative Colitis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Disease Type
  • 7.3.5. Spain Ulcerative Colitis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Disease Type

8. Asia Pacific Ulcerative Colitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Ulcerative Colitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Disease Type
  • 8.3.2. India Ulcerative Colitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Disease Type
  • 8.3.3. Japan Ulcerative Colitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Disease Type
  • 8.3.4. South Korea Ulcerative Colitis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Disease Type
  • 8.3.5. Australia Ulcerative Colitis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Disease Type

9. Middle East & Africa Ulcerative Colitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Ulcerative Colitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Disease Type
  • 9.3.2. UAE Ulcerative Colitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Disease Type
  • 9.3.3. South Africa Ulcerative Colitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Disease Type

10. South America Ulcerative Colitis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Ulcerative Colitis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Disease Type
  • 10.3.2. Colombia Ulcerative Colitis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Disease Type
  • 10.3.3. Argentina Ulcerative Colitis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Disease Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Ulcerative Colitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Johnson and Johnson
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Allergan, Inc.
• 15.3. Merck & Co., Inc.
• 15.4. Novartis AG
• 15.5. Bausch Health Companies Inc.
• 15.6. AstraZeneca Plc
• 15.7. Eli Lilly & Company
• 15.8. Pfizer Inc.
• 15.9. Sanofi SA
• 15.10. GlaxoSmithKline Plc.

16. Strategic Recommendations

17. About Us & Disclaimer